11/23/2023 0 Comments Dapagliflozin declare trialobstructive sleep apnea medical devicesSodium-glucose. Only canagliflozin increases the risk of amputations (RR increase 26%) & fractures (RR increase by 11%). The cardiovascular (CV) benefits of dapagliflozin were first observed in the DECLARE-TIMI 58 trial. A composite endpoint of cardiovascular death or hospitalisation for heart failure was. SGLT2 inhibitors do not reduce/increase stroke Īll SGLT2 inhibitors reduce the risk of HF hospitalization (RRR ~30%), regardless of prior ASCVD or HF.Īll SGLT2 inhibitors increase the risk of DKA (RR increase by 120%) The DECLARE-TIMI 58 trial with dapagliflozin had two co-primary endpoints. SGLT2 inhibitors reduce the risk of major adverse CV events (composite of CV death/MI/stroke) in patients with existing ASCVD (RRR 14%), but not in those without ASCVD Conclusion: The DECLARETIMI 58 trial is testing the hypotheses that dapagliflozin is safe (does not increase) and may reduce the occurrence of major CV. (2019) questioned the CV benefits of the third SGLT2 inhibitor, dapagliflozin, in the randomized, double-blinded, placebo-controlled trial. Only empagliflozin clearly reduces all-cause & CV mortality (in patients with existing ASCVD, RRR 32%) high rate of exclusion during placebo run-in)Ī meta-analysis of the 3 major CV outcome trials of SGLT2 inhibitors (CANVAS, DECLARE & EMPA-REG) shows the following overall patterns: Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial Diabetes JAMA Cardiology JAMA Network Figure 1. Multiple risk factors: Male 55+ y/o or female 60+ y/o + tobacco use, HTN, or LDL >3.3 mmol/LĦ4 y/o, male (63%), white (80%), North American (32%)ĪSCVD (41%): CAD (33%), PAD (6%), CVA (8%)ĮGFR 85 (7% with eGFR 17,160 randomized (i.e. Here we report analyses of renal outcomes with the SGLT2 inhibitor dapagliflozin in the DECLARE-TIMI 58 cardiovascular outcomes trial, which included. ![]() Overall assessment of the evidence for SGLT2 inhibitors shows several differences between agents in this class empagliflozin appears to have the greatest potential for benefit, whereas canagliflozin has the highest potential for harm.Ĭontext: Summaries of EMPA-REG with empagliflozin & CANVAS with canagliflozinĮstablished atherosclerotic cardiovascular disease (ASCVD IHD, ischemic CVA, PAD) & 40+ y/o Dapaglifozin increases the risk of fungal genital infections (NNH 125) & DKA (NNH 500). In the substudy of DECLARE-TIMI-58 conducted by Kato et al.,6 dapagliflozin therapy reduced HHF both in patients with and without heart failure or reduced. NEJM Bottom line: In patients with type 2 diabetes with existing ASCVD or with multiple CV risk factors, dapagliflozin did not reduce the risk of a composite of major adverse cardiovascular events however, it did reduce the risk of HF hospitalizations (NNT 125) at 4.2 years. Cardiovascular outcomes trials (CVOTs) of sodiumglucose cotransporter 2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Dapagliflozin effect on CardiovascuLAR Events trial DECLARE-TIMI 58.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |